US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Maze Therapeutics (MAZE) Six Month Summary: A Volatile Debut with High-Stakes Catalysts Ahead

Maze Therapeutics Inc. (MAZE): Phase 2 Biopharma Targeting Kidney Disease Files for IPO.

Maze Therapeutics Inc. (MAZE): Kidney Biotech with Blockbuster Potential Sets Terms for IPO

Maze Therapeutics Inc. (MAZE): Kidney Disease Biotech IPO Garnering Attention from Sector Investors

IPOs and Secondary Offerings

Equity Capital Markets

Maze Therapeutics / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/maze-therapeutics-inc" target="_blank" data-smartkarma-citation="entities:44247:1" rel="noopener">Maze Therapeutics (MAZE US)</a> upsized its transaction but saw its IPO price dip below issue on day one.</li>
<li>A critical piece of information, price guidance, was missing from the final channel check sending a warning message to the market.</li>
<li>With the lack of enthusiasm for this IPO during its first session, we would encourage investors to exercise caution on this IPO in the aftermarket.</li>
</ul>



Maze Therapeutics (MAZE US) upsized its transaction but saw its IPO price dip below issue on day one.
A critical piece of information, price guidance, was missing from the final channel check sending a warning message to the market.
With the lack of enthusiasm for this IPO during its first session, we would encourage investors to exercise caution on this IPO in the aftermarket.


Maze Therapeutics (MAZE): Upsized IPO Slumps in the Aftermarket